Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose Blinded Extension Study to the CBAF312A2201 Study to Evaluate Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

Trial Profile

A Dose Blinded Extension Study to the CBAF312A2201 Study to Evaluate Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally Once Daily in Patients With Relapsing-remitting Multiple Sclerosis

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Oct 2018

At a glance

  • Drugs Siponimod (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms BOLD EXTENSION
  • Sponsors Novartis
  • Most Recent Events

    • 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 28 Feb 2017 Status changed from recruiting to completed.
    • 19 Dec 2016 This trial has been completed in Hungary (end date: 10 Oct 2016) according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top